MultiOmics Inc. develops LiquidMammo™, a microRNA‑based blood test designed to complement imaging and support early detection across diverse patient populations.
MultiOmics Inc. is a molecular diagnostics company developing tools for earlier disease detection. Our team spans molecular biology, biostatistics, diagnostics, and population‑level screening research.
We aim to enhance breast‑cancer screening by adding biological insights that complement mammography, particularly in women with dense breasts where early detection is most challenging.
MultiOmics Inc. is headquartered in Washington, DC, and operates from LabCentral in Cambridge, MA — the MIT‑adjacent biotech innovation hub.
LiquidMammo analyzes dysregulation patterns in circulating microRNAs — small, stable RNA molecules associated with tumor biology — to capture early biological signals.
Our proprietary panel integrates multiple microRNAs to improve reproducibility and performance across heterogeneous patient populations.
Adding molecular information to imaging strengthens interpretive confidence and supports early decision‑making, particularly in women with dense breasts.
The founding team brings expertise in diagnostics, assay development, biostatistics, and clinical research.
Breast‑imaging radiologists and oncology specialists guide clinical deployment and screening strategy.
MultiOmics collaborates with academic researchers to refine performance, validate utility, and study diverse populations.
A non‑invasive complement to imaging that helps clarify uncertain results and support earlier detection in dense‑breast populations.
Actionable molecular information that integrates naturally into existing clinical workflows without added burden.
The demand for liquid‑biopsy early detection is growing. The CLIA LDT model enables rapid iteration and real‑world scaling.